How nicotine use may worsen brain inflammation and thinking in people with HIV
Neuroimmune and Cognitive Consequences of Nicotine Use in a Rodent Model of HIV: Implications for Anti-Retroviral Therapies
Researchers are looking at whether nicotine exposure makes brain inflammation and thinking problems worse for people living with HIV.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11195163 on NIH RePORTER |
What this research studies
This project uses a rat model that mimics voluntary nicotine use to explore how smoking-like behavior changes immune signals in brain regions linked to thinking and anxiety. Scientists will measure inflammatory molecules in blood and in brain areas such as the nucleus accumbens, prefrontal cortex, and amygdala, and examine microglial (brain immune cell) responses. The team will compare males and females to see if one sex is more vulnerable and connect brain findings to markers in the blood. Results aim to explain why cognitive and mood problems persist in people with HIV despite antiretroviral therapy.
Who could benefit from this research
Good fit: People living with HIV who use nicotine-containing products or who are concerned about cognitive or mood symptoms may be interested in related future studies or trials informed by this research.
Not a fit: People without HIV or who never use nicotine products are unlikely to see direct benefit from this specific line of research.
Why it matters
Potential benefit: If successful, the work could point to biological targets or strategies to reduce nicotine-related brain inflammation and protect thinking in people living with HIV.
How similar studies have performed: Clinical data show that people with HIV smoke more and have persistent cognitive problems, and some animal work links nicotine to neuroimmune changes, but the specific nicotine–HIV brain interactions examined here remain underexplored.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Gipson-Reichardt, Cassandra D — University of Kentucky
- Study coordinator: Gipson-Reichardt, Cassandra D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.